Last week, the leading developers of treatments for atrial fibrillation (AFib) convened in Boston for the 2026 AF Symposium.

Boston Scientific has announced new data backing its Farapulse pulsed field ablation (PFA) platform for treating AFib.

Abbott on Friday presented one-year clinical trial results for the Volt pulsed field ablation system alongside six-month CE ...

Coherent Sine-Burst Electroporation™ Platform demonstrates 100% procedural success and high freedom from AF in paroxysmal and persistent ...

Pulse Biosciences PLSE recently announced late-breaking data from its first-in-human feasibility study of the nPulse Cardiac ...

Johnson & Johnson, Boston Scientific and Abbott were among the companies showcasing new data on atrial fibrillation ...

At 1 year, nearly 80% of patients with atrial fibrillation treated with an FDA-approved spherical pulsed field ablation ...

Advanced Cardiac Therapeutics raised $45 million in equity, which will drive a global clinical development program for its next-generation ablation catheter for the treatment of atrial fibrillation ...

New research from CU Anschutz scientists suggests that staying physically active after heart rhythm treatment may ...

Please provide your email address to receive an email when new articles are posted on . “The current practice of radiofrequency ablation with power-controlled irrigated catheters involves the delivery ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a navigation-enabled ablation catheter for the treatment of ...

Boston Scientific missed consensus for its electrophysiology segment by $33 million due to increased competition in the pulsed-field ablation market. Boston Scientific’s electrophysiology business ...